共 44 条
[1]
Ando Y(2013)Guideline of transthyretin-related hereditary amyloidosis for clinicians Orphanet Journal of Rare Diseases 8 31-2466
[2]
Coelho T(2015)Diagnosis, prognosis, and therapy of transthyretin amyloidosis Journal of the American College of Cardiology 66 2451-588
[3]
Berk JL(2019)Neuropathy associated with systemic amyloidosis Seminars in Neurology 39 578-638
[4]
Gertz MA(2015)Evolving landscape in the management of transthyretin amyloidosis Annals of Medicine 47 625-76
[5]
Benson MD(2013)THAOS - the Transthyretin amyloidosis outcomes survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis Current Medical Research and Opinion 29 63-S112
[6]
Dyck PJ(2017)Hereditary ATTR amyloidosis: Burden of illness and diagnostic challenges The American Journal of Managed Care 23 S107-175
[7]
Kaku M(2019)Burden of hereditary transthyretin amyloidosis on quality of life Muscle & Nerve 60 169-26
[8]
Berk J(2019)Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis Circulation. 140 16-408
[9]
Hawkins PN(2010)Transthyretin-related amyloidoses and the heart: A clinical overview Nature Reviews. Cardiology 7 398-842
[10]
Ando Y(2015)Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses Orphanet Journal of Rare Diseases 10 A436-55